

Applicants : Philip Livingston and Friedhelm Helling
U.S. Serial No.: 08/477,097
Filed : June 7, 1995
Page 2

In the claims:

Please cancel claim 93 without disclaimer or prejudice to applicants right to pursue the subject matter of this claim in a later-filed application. Please also amend claims 94-96 and 98-99 under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material as follows:

--94. (Amended) A method of [preventing or] treating a cancer in a subject which comprises administering to the subject an effective cancer [preventing or] treating amount of a composition which comprises:

- a) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion, to ii) Keyhole Limpet Hemocyanin;
- b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and
- c) a pharmaceutically acceptable carrier;

the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in the subject,

wherein in the conjugate the ganglioside derivative is conjugated to Keyhole Limpet Hemocyanin through a ceramide-derived carbon of the ganglioside derivative to Keyhole Limpet Hemocyanin, so as to thereby [prevent or treat] a cancer in the subject.--

--95. (Amended) The method of claim [93 or] 94, wherein the cancer is of epithelial origin.--

--96. (Amended) The method of claim [93 or] 94, wherein the cancer is of neuroectodermal origin.--